• Determine the dose-related effect of treatment with rosuvastatin on production & fractional catabolism of apolipoprotein A-I (apoA-I) and apolipoprotein A-II (apoA-II), & on the plasma apoA-I, apoA-II & high-density lipoprotein cholesterol (HDL-C) c
  

• Determine the dose-related effect of treatment with rosuvastatin on cellular cholesterol efflux,total cholesterol, low-density lipoprotein cholesterol (LDL-C), non-LDL-C, triglyceride & pre1-HDL concentrations,HDL2,HDL3 cholesterol ratio
  
• Cholesteryl ester transfer protein (CETP) and lecithin:cholesterol acyl transferase (LCAT) activity
  
• Lathosterol and campesterol, total apolipoprotein B (apoB), nonesterified fatty acids (NEFA) and apolipoprotein C-III (apoC-III) plasma concentrations.
  

Inclusion Criteria:

• Signed informed consent
• male aged 30 to 70 years of age
• LDL-C <6 mmol/L
• HDL-C ≤1.2 mmol/L
• at least 2 of the following:
• insulin resistance (fasting glucose >6 mmol/L or insulin >10 mU/L or HOMA score >2.5)
• central obesity (waist circumference >=94 cm).
• plasma triglycerides >=1.7 and <4.5 mmol/L.
• blood pressure >=130/ >=85 mm Hg or on drug treatment for hypertension

Exclusion Criteria:

• LDL cholesterol >=6 mmol/L
• pre-existing or history of cardiovascular disease, diabetes, renal dysfunction, anaemia, history of significant dyspepsia or gastrointestinal disease
• apolipoprotein genotype E2/E2